Aurealis EVENTS
European Wound Management Association 2026 Conference
Aurealis Therapeutics will share the results of its DIAMEND Phase 2 clinical trial of AUP-16 for non-healing Diabetic Foot Ulcers (DFUs) at the European Wound Management Association (EWMA) 2026 Conference,...
Week of Strategic Meetings in China 2025
During the week of 20–25 October 2025, Aurealis Therapeutics’ CEO Juha Yrjänheikki and COO Laurent Décory traveled to Beijing, Shanghai and Hong Kong for a series of high-level meetings with...
World Drug Safety Congress Europe 2025
Aurealis Therapeutics Drug Safety Officer, Matleena Piiroinen, attended the World Drug Safety Congress Europe 2025, that took place 7–8 October in Amsterdam, The Netherlands. As Europe’s leading forum for drug...
LSX World Congress USA 2025
Aurealis Therapeutics attended LSX World Congress USA, 16-17 September 2025 in Boston. This was a leading forum that brought together innovators, investors, and senior life science dealmakers to shape the...
Biotech Week Boston 2025
Aurealis Therapeutics CEO, Juha Yrjänheikki, and COO, Laurent Décory, attended the Biotech Week Boston from 15-18 September 2025 in Boston, USA.
Partnering Week in China 2025
Aurealis Therapeutics team visited China from June 9–13, 2025, for a dedicated partnering week. Juha Yrjänheikki (CEO), Laurent Décory (COO), Hanna-Riikka Kärkkäinen (Director, Quality & Regulatory Affairs), and Jere Kurkipuro...